1.1.1 — Medication-Related Problem Framework

• NAPLEX questions often hide the real task inside extra details; the medication-related problem framework tells you what the pharmacist must solve first.
• The same drug can create different problems in different patients: one stem tests missing indication, another tests underdosing, another tests safety, and another tests adherence.
• This framework prevents out-of-scope thinking by keeping your focus on pharmacist actions: review, clarify, recommend, hold, monitor, counsel, and escalate when needed.
• It is the foundation for upcoming topics on best next pharmacist action and order verification priorities.

1.1.1.1 Key terms

• Medication-related problem (MRP): Any issue preventing a medication from being indicated, effective, safe, or usable.
• Indication: Whether a medication is needed and appropriate for a recognized treatment goal.
• Untreated indication: A condition needing drug therapy but no appropriate medication is present.
• Unnecessary therapy: A medication exists without a current valid reason, or duplicates another therapy.
• Effectiveness: Whether the therapy can achieve the desired outcome for this patient.
• Subtherapeutic dose: Dose, route, interval, formulation, or duration is insufficient.
• Wrong drug for condition: A medication is used, but it is not the best therapeutic choice for the patient’s problem.
• Safety: Whether risks outweigh benefits for this patient at this dose and under these circumstances.
• Adverse drug reaction: Harmful or intolerable effect at usual doses.
• Dose too high: Toxicity risk from dose, accumulation, interaction, organ dysfunction, or duplicate exposure.
• Adherence/nonadherence: Failure to take or obtain therapy as intended.
• Administration barrier: Patient cannot use dosage form, device, timing, or technique correctly.
• Monitoring failure: Needed labs, vitals, symptoms, or follow-up are missing.
• Clarification threshold: The point at which the pharmacist should stop verification and obtain missing or conflicting information.

1.1.1.2 Must-know facts

• The four high-yield buckets are indication, effectiveness, safety, and adherence/practical use.
• Ask first: Does the patient need this drug? before asking whether the dose is correct.
• Two drugs for the same purpose may signal duplicate/unnecessary therapy, not stronger treatment.
• Normal dose does not mean safe dose in renal impairment, hepatic impairment, older age, pregnancy, or major interactions.
• A drug can be ineffective even when “on board” if the dose, formulation, route, interval, or device technique is wrong.
• Adherence problems are medication-related problems even when the prescription itself is technically correct.
• When the order is incomplete or unsafe, the pharmacist action is hold and clarify, not guess.
• Urgent toxicity, anaphylaxis, severe bleeding, or major interaction risk shifts the action from routine verification to escalation.

flowchart TD
A[Medication order or patient case] --> B{First question}
B -->|Drug needed?| C[Indication]
B -->|Will it work?| D[Effectiveness]
B -->|Could it harm?| E[Safety]
B -->|Can patient use it?| F[Adherence or practical use]
C --> C1[Untreated indication]
C --> C2[Unnecessary or duplicate therapy]
D --> D1[Wrong drug]
D --> D2[Dose too low or wrong formulation]
E --> E1[Adverse effect or contraindication]
E --> E2[Dose too high or interaction]
F --> F1[Nonadherence]
F --> F2[Technique or access barrier]

Use this as your first sorting tool. See Fig 1.

1.1.1.3 Foundational sorting: identify the primary medication-related problem

A Explanation

The main decision conflict is whether the stem is really about starting/stopping a therapy or about fixing an existing therapy. The single rule that resolves it is this: if the patient lacks an appropriate therapy or has therapy without need, classify it as indication first. Only after indication is settled should you move to effectiveness, safety, or adherence. WHY THIS IS TESTED: NAPLEX stems often include a distracting abnormal lab or side effect, but the most urgent or primary pharmacist task is recognizing that the patient either needs therapy that is missing or is receiving a therapy that should not be there.

Choose untreated indication when there is a clear therapeutic need and no appropriate medication exists. Choose unnecessary therapy when the drug has no current indication, duplicates another drug for the same purpose, or is treating an avoidable side effect of another medication instead of the root cause. Reject “dose too low” when the more basic problem is that the chosen drug is not needed at all. Reject “adherence” when the patient is perfectly adherent to a medication that should never have been continued.

flowchart TD
A[Case stem] --> B{Is there a clear untreated condition?}
B -->|Yes| C[Untreated indication]
B -->|No| D{Is there a duplicate or no-current-need drug?}
D -->|Yes| E[Unnecessary therapy]
D -->|No| F{Therapy present but not meeting goal?}
F -->|Yes| G[Effectiveness problem]
F -->|No| H{Risk outweighs benefit?}
H -->|Yes| I[Safety problem]
H -->|No| J[Adherence or use barrier]

When several answer choices look plausible, return to the sequence in See Fig 2.

B Worked example

A 67-year-old man presents to the pharmacy for refill synchronization. His profile includes metformin 1000 mg by mouth twice daily, insulin glargine 24 units nightly, lisinopril 20 mg daily, atorvastatin 40 mg nightly, and duplicate acid suppression with omeprazole 20 mg daily plus pantoprazole 40 mg daily from a recent discharge. He has type 2 diabetes, hypertension, and GERD. His wife reports excellent adherence. A recent fasting glucose of 168 mg/dL is listed, which tempts you to focus on diabetes intensification. The board-style task asks for the most likely medication-related problem requiring clarification before routine refill.

Reasoning chain: Identify task: name the primary MRP. Extract key facts: duplicate PPIs, no evidence of two different indications, strong adherence, elevated glucose but already on active therapy. Apply rule: ask first whether any drug is unnecessary. Omeprazole and pantoprazole are therapeutic duplicates for the same purpose. Eliminate distractors: “dose too low” for diabetes is tempting because glucose is above goal, but that is not the most basic problem requiring refill clarification. “Nonadherence” is contradicted by refill sync and spouse report. Verify: the clearest immediate category is unnecessary/duplicate therapy under indication.

C Exam trap

D Checkpoint

Question: A 58-year-old woman with atrial fibrillation, osteoarthritis, and chronic insomnia brings a profile containing apixaban 5 mg by mouth twice daily, ibuprofen 600 mg three times daily as needed, and two active sleep agents: trazodone 50 mg nightly and zolpidem 10 mg nightly from different prescribers. She reports taking all medications exactly as labeled. Which medication-related problem is the best primary classification for the two sleep agents?

1. A. Untreated indication — Tempting because insomnia is present, but incorrect because therapy is already present; the issue is not absence of treatment.
2. B. Unnecessary therapy — Correct because two hypnotic therapies for the same symptom raise duplicate-therapy concern unless a clear rationale exists.
3. C. Dose too low — Tempting because insomnia persists in many patients, but incorrect because the discriminating clue is duplication, not underdosing.
4. D. Nonadherence — Tempting because sleep medications are often taken inconsistently, but incorrect because she reports taking them exactly as directed and the profile itself shows the problem.

1.1.1.4 Foundational refinement: distinguish effectiveness problems from safety problems

A Explanation

The central conflict here is choosing between “this therapy is not enough” and “this therapy may cause harm”. The single rule that resolves it is this: if the regimen could plausibly work but patient-specific risk makes it dangerous, choose safety; if the regimen is too weak, wrong, or poorly matched to the condition, choose effectiveness. WHY THIS IS TESTED: Many NAPLEX stems give an abnormal value and a risky comorbidity at the same time. The exam wants to know whether you prioritize better control or harm prevention.

Choose effectiveness when the drug is the wrong agent, the dose is too low, the interval is too long, the route is inappropriate, or the dosage form prevents adequate exposure. Choose safety when the same regimen creates toxicity risk through renal accumulation, drug interaction, contraindication, allergy, excessive dose, duplicate exposure, or adverse effect pattern. A key discriminator is whether you would increase/change therapy versus hold/reduce/avoid therapy. See Fig 3 for the compare-and-choose framework.

B Worked example

A 74-year-old woman with heart failure, chronic kidney disease, and atrial fibrillation is discharged on digoxin 0.25 mg by mouth daily, furosemide 40 mg daily, and amiodarone 200 mg daily. Her serum creatinine increased from 0.9 to 1.6 mg/dL over two months, and she now reports nausea and yellow vision changes. A BNP value remains elevated, which tempts you to focus on heart failure effectiveness. The task asks for the most likely medication-related problem requiring immediate pharmacist intervention.

Reasoning chain: Identify task: classify the dominant problem. Extract key facts: older age, worsening renal function, digoxin dose, amiodarone interaction, classic digoxin toxicity symptoms. Apply rule: when a regimen could cause harm and the fix is reduction/hold rather than intensification, choose safety. Eliminate distractors: “effectiveness problem” is tempting because heart failure is not fully controlled, but elevated BNP is noise compared with toxicity clues. “Adherence” is not supported. Verify: the primary problem is safety: dose too high / interaction-related toxicity risk.

C Exam trap

D Checkpoint

Question: A 63-year-old man with type 2 diabetes, CKD stage 4, and neuropathy presents with a refill request for gabapentin 900 mg by mouth three times daily. He reports new excessive sedation and unsteady gait but says his foot pain is still bothersome. Which is the best primary medication-related problem category?

1. A. Untreated indication — Tempting because neuropathy remains symptomatic, but incorrect because the patient already has therapy for the indication.
2. B. Dose too low — Tempting because pain persists, but incorrect because CKD plus sedation and gait instability point to accumulation and harm.
3. C. Safety problem — Correct because renal impairment and toxicity symptoms make the dominant issue dose-related harm.
4. D. Nonadherence — Tempting because variable pain control can reflect inconsistent use, but incorrect because the discriminating clues are adverse effects with organ dysfunction.

1.1.1.5 Applied patient review: find the clue that reclassifies the problem

A Explanation

This section moves from category names to pattern recognition in real profiles. The decision conflict is whether the patient data are merely background or the single discriminating clue that changes the MRP category. The rule: when a patient factor changes appropriateness of the regimen—renal function, allergy, age, pregnancy, comorbidity, or interacting medication—that factor can reclassify a problem from routine dosing to safety or from apparent failure to practical-use failure. WHY THIS IS TESTED: board-style cases frequently add one line of data that flips the answer from simple dose adjustment to hold-and-clarify.

Examples: uncontrolled asthma on albuterol may look like undertreatment, but if the patient never uses the inhaler correctly, the core MRP is adherence/practical use. A PPI with poor symptom control may look ineffective, but if the patient is taking it after meals only intermittently, the problem is administration/adherence. A standard antibiotic dose may look fine, but if the patient has an immediate penicillin anaphylaxis history and cross-reactivity concern in the stem, safety becomes primary. In pharmacy practice, the best pharmacist action depends on the dominant driver, not every issue present.

flowchart LR
A[Regimen looks straightforward] --> B{Key patient clue}
B -->|Poor technique or missed doses| C[Adherence or practical use]
B -->|Kidney or liver decline| D[Safety: accumulation risk]
B -->|Duplicate agent from transition of care| E[Indication: unnecessary therapy]
B -->|No contraindication, but poor control| F[Effectiveness]
C --> G[Counsel or simplify]
D --> H[Hold, reduce, clarify]
E --> I[De-duplicate]
F --> J[Optimize or switch]

When you feel two options are equally plausible, ask which single patient clue does the sorting. See Fig 4.

B Worked example

A 49-year-old man with asthma, obesity, and GERD requests an early refill for fluticasone/salmeterol 250/50 one inhalation twice daily and albuterol HFA two puffs every 4 hours as needed. He reports “the steroid inhaler never works,” has nighttime symptoms three times weekly, and also takes omeprazole 20 mg daily. His peak flow log is inconsistent. During counseling, he demonstrates activating the dry powder inhaler after exhaling directly into the device. The distracting clue is that he uses albuterol several times daily, which makes dose escalation look attractive.

Reasoning chain: Identify task: classify the most likely current MRP. Extract key facts: controller present, symptoms uncontrolled, technique error with dry powder inhaler, inconsistent peak flow log. Apply rule: if the regimen could work but the patient cannot use it correctly, the primary problem is adherence/practical use rather than pure ineffectiveness. Eliminate distractors: “dose too low” is tempting because symptoms persist; “untreated indication” is wrong because therapy exists. Verify: the best classification is adherence/practical-use problem due to device technique.

C Exam trap

D Checkpoint

Question: A 31-year-old woman with epilepsy, hypothyroidism, and iron deficiency takes levothyroxine 100 mcg by mouth every morning, ferrous sulfate 325 mg with breakfast, and calcium carbonate 500 mg three times daily. Her TSH remains elevated despite timely refills and she denies missed doses. Which medication-related problem best fits the levothyroxine issue?

1. A. Untreated indication — Tempting because TSH is elevated, but incorrect because hypothyroidism is already being treated.
2. B. Effectiveness problem — Correct because interacting administration with iron and calcium reduces absorption, making the regimen ineffective as used.
3. C. Safety problem — Tempting because drug interactions are involved, but incorrect because the interaction here mainly causes subtherapeutic effect rather than toxicity.
4. D. Unnecessary therapy — Tempting if one focuses on supplement duplication, but incorrect because the question asks specifically about levothyroxine not reaching goal.

1.1.1.6 Integration: convert the framework into the safest pharmacist action

A Explanation

The final decision conflict is not just naming the category but choosing the right pharmacist move within scope. The rule is simple: the category predicts the action. Indication problems often lead to recommendation or clarification. Effectiveness problems usually lead to optimization, formulation correction, counseling, or monitoring recommendations. Safety problems most often lead to hold, urgent clarification, dose reduction recommendations, or escalation. Adherence/practical-use problems lead to counseling, simplification, refill coordination, affordability troubleshooting, or technique correction. WHY THIS IS TESTED: on NAPLEX, the best answer is often not the disease-management ideal but the safest pharmacist action supported by the data in the stem.

Choose hold and clarify when critical information is missing, the order is internally inconsistent, there is significant contraindication risk, or urgent harm is possible. Choose recommend when the problem is clear but implementation requires prescriber involvement. Choose counsel and verify understanding when the prescription is otherwise appropriate and the barrier is use-related. Reject out-of-role options such as independently diagnosing a new condition or unilaterally prescribing changes without authority. See Fig 5 for the action ladder.

B Worked example

A 72-year-old woman with osteoarthritis, hypertension, and CKD stage 3 presents with a new prescription for trimethoprim/sulfamethoxazole DS 1 tablet by mouth twice daily for 10 days while taking warfarin 5 mg nightly and lisinopril 20 mg daily. She has a documented sulfonamide antibiotic rash history listed as “hives,” but the prescriber note is not attached. Her INR last week was 2.4. The tempting but wrong clue is that the dose itself looks standard and the infection has already been diagnosed. The question asks for the best pharmacist action before dispensing.

Reasoning chain: Identify task: choose action, not diagnosis. Extract key facts: possible antibiotic allergy, major warfarin interaction, renal impairment, standard dose but high safety concern. Apply rule: safety problem with significant missing clarification and interaction risk predicts hold and contact prescriber. Eliminate distractors: counseling only is insufficient; changing therapy independently is out of role; dispensing with extra monitoring ignores the unresolved allergy and interaction concern. Verify: the safest action is hold dispensing and clarify with the prescriber.

C Exam trap

D Checkpoint

Question: A 66-year-old man with COPD, diabetes, and limited vision has correct refills on tiotropium inhalation daily and metformin 1000 mg twice daily. He says he “cannot tell which inhaler cap goes where,” and his wife reports frequent confusion about administration times. The prescription directions are accurate and no urgent contraindication is present. What is the best next pharmacist action category linkage?

1. A. Safety → hold dispensing immediately — Tempting because misuse can cause harm, but incorrect because no urgent toxicity or contraindication is present; the dominant issue is practical use.
2. B. Adherence/practical use → counsel and simplify the regimen — Correct because the primary problem is the patient’s ability to use the medications accurately.
3. C. Indication → recommend adding another inhaler — Tempting because COPD symptoms may persist, but incorrect because the stem emphasizes confusion, not missing therapy.
4. D. Effectiveness → increase tiotropium dose — Tempting because poor disease control may result, but incorrect because device confusion must be addressed first.

• Most common wrong answer and why: Choosing “dose too low” whenever disease control is imperfect. This is tempting because exams often show one value above goal. Reject it when there is a more basic clue such as duplication, contraindication, technique failure, or nonadherence.
• Looks similar but isn’t: Uncontrolled disease due to missed doses is not the same as wrong drug or low dose. The regimen may be correct on paper but ineffective in real life because it is not being used properly.
• Related future trap: In the upcoming Best Next Pharmacist Action topic, some options will all describe helpful things to do. The winning answer will be the safest action for the dominant MRP category, not the most comprehensive list.
• Related future trap: In Order Verification Priorities, learners may focus on product selection before asking whether the therapy itself is indicated and safe. The framework in this lesson should come first.

If the stem says renal decline + sedation + same dose, think safety from accumulation.

If the stem says two active agents for the same purpose after hospitalization, think unnecessary/duplicate therapy.

If the stem says refills are timely but administration timing conflicts with food or supplements, think effectiveness problem caused by use pattern.

If the stem says patient demonstrates poor device technique, think adherence/practical-use barrier before dose escalation.

If the stem says allergy history is unresolved and a risky order arrives, think hold and clarify before dispensing.

flowchart TD
A[Read medication context: drug dose route frequency] --> B[Define treatment purpose]
B --> C{Indication problem?}
C -->|Yes| D[Start stop or de-duplicate recommendation]
C -->|No| E{Effectiveness problem?}
E -->|Yes| F[Optimize or switch]
E -->|No| G{Safety problem?}
G -->|Yes| H[Hold clarify reduce or escalate]
G -->|No| I[Adherence or practical-use intervention]
H --> J[Document and communicate]
F --> J
D --> J
I --> J

Keep this sequence visible during practice sets. See Fig 6.

• Untreated indication → clear need with no appropriate therapy present
• Unnecessary therapy → active drug without current purpose or duplicated purpose
• Wrong drug → therapy present but poor fit for the patient or condition
• Dose too low → more therapy would solve the problem
• Safety problem → less therapy, holding, or avoidance would solve the problem
• Adherence issue → profile may be correct while real-world use is not
• Technique failure → classify as practical-use barrier before assuming drug failure
• Interaction lowering exposure → effectiveness problem more than toxicity problem
• Interaction increasing exposure → safety problem more than underdosing problem
• Duplicate inpatient-to-outpatient carryover → indication problem first
• Renal decline with toxicity symptoms → safety even if the labeled dose looks standard
• Abnormal value alone → not enough; find the clue that tells you why
• Best pharmacist action → must fit category and stay within scope